Clinical Trial

Reduced-dose Botox for Urgency Incontinence Among Elder Females

Study acronym: RELIEF
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to study the treatment of urgency urinary incontinence (UUI), specifically among women 70 years and older, by comparing reduced versus standard dose of onabotulinumtoxinA (BTX; trade name BOTOX(c)) injection in the bladder.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-08-19; most recent amendment 2026-02-01.
Status change: Recruiting → Active, Not Recruiting 2026-02-01
Status change: Not Yet Recruiting → Recruiting 2023-05-11
Trial Details
NCT Number NCT05512039
Lead Sponsor Dartmouth-Hitchcock Medical Center
Collaborators: Patient-Centered Outcomes Research Institute, Dartmouth College, University of Alabama at Birmingham, University of Pittsburgh, University of Texas, Kaiser Permanente, Oregon Health and Science University, Stanford University, University of Connecticut, University of Nebraska
Conditions Overactive Bladder, Urinary Incontinence in Old Age, Urgency Urinary Incontinence
Enrollment 376 participants
Start Date 2023-05-12
Primary Completion 2026-09-01 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-03